Cargando…

BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis

BACKGROUND: Anti-EGFR antibody–based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations—including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification—are associated with the mechanisms underlying the development of resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nam, Soo Kyung, Yun, Sumi, Koh, Jiwon, Kwak, Yoonjin, Seo, An Na, Park, Kyoung Un, Kim, Duck-Woo, Kang, Sung-Bum, Kim, Woo Ho, Lee, Hye Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798471/ https://www.ncbi.nlm.nih.gov/pubmed/26991109 http://dx.doi.org/10.1371/journal.pone.0151865

Ejemplares similares

Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer
por: Kwak, Yoonjin, et al.
Publicado: (2016)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
por: Zeng, Juanzi, et al.
Publicado: (2023)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
por: Kwak, Yoonjin, et al.
Publicado: (2017)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Stromal Expression of MicroRNA-21 in Advanced Colorectal Cancer Patients with Distant Metastases
por: Lee, Kyu Sang, et al.
Publicado: (2016)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer
por: Wang, Chengfeng, et al.
Publicado: (2022)

High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment
por: Koh, Jiwon, et al.
Publicado: (2020)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
por: Mao, Chen, et al.
Publicado: (2012)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Patra, Satyajit, et al.
Publicado: (2017)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
por: Reggiani Bonetti, Luca, et al.
Publicado: (2018)

Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
por: Yun, Sumi, et al.
Publicado: (2018)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
por: Brinzan, Costel Stelian, et al.
Publicado: (2022)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
por: Adams, Richard, et al.
Publicado: (2017)

The Clinical Implication of Cancer-Associated Microvasculature and Fibroblast in Advanced Colorectal Cancer Patients with Synchronous or Metachronous Metastases
por: Kwak, Yoonjin, et al.
Publicado: (2014)

Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer
por: Jing, Changwen, et al.
Publicado: (2018)

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas()()
por: Myers, Meagan B., et al.
Publicado: (2016)

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
por: Velho, Sérgia, et al.
Publicado: (2008)

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
por: Lurkin, Irene, et al.
Publicado: (2010)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
por: Brandi, Giovanni, et al.
Publicado: (2012)

Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA
por: Chang, Li-Chun, et al.
Publicado: (2014)

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
por: Mao, Chen, et al.
Publicado: (2015)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

Energy balance‐related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance
por: Morkel, Markus, et al.
Publicado: (2015)

Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer
por: Kwak, Yoonjin, et al.
Publicado: (2020)

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
por: Zhang, Jing, et al.
Publicado: (2015)

Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients
por: Li, Xiaozhou, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u1i5uqea54dubbudhc6ec4o2l6